134 related articles for article (PubMed ID: 38508233)
21. The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy.
Mabeta P; Steenkamp V
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555234
[TBL] [Abstract][Full Text] [Related]
22. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1.
Hazarika S; Dokun AO; Li Y; Popel AS; Kontos CD; Annex BH
Circ Res; 2007 Oct; 101(9):948-56. PubMed ID: 17823371
[TBL] [Abstract][Full Text] [Related]
23. Differential expression of VEGF ligands and receptors in prostate cancer.
Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
[TBL] [Abstract][Full Text] [Related]
24. Stimulatory Effect of Vascular Endothelial Growth Factor on Proliferation and Migration of Porcine Trophectoderm Cells and Their Regulation by the Phosphatidylinositol-3-Kinase-AKT and Mitogen-Activated Protein Kinase Cell Signaling Pathways.
Jeong W; Kim J; Bazer FW; Song G
Biol Reprod; 2014 Mar; 90(3):50. PubMed ID: 24451985
[TBL] [Abstract][Full Text] [Related]
25. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies.
Shibuya M
Genes Cancer; 2011 Dec; 2(12):1097-105. PubMed ID: 22866201
[TBL] [Abstract][Full Text] [Related]
26. Molecular targeting of VEGF/VEGFR signaling by the anti-VEGF monoclonal antibody BD0801 inhibits the growth and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo.
Liu L; Qin S; Zheng Y; Han L; Zhang M; Luo N; Liu Z; Gu N; Gu X; Yin X
Cancer Biol Ther; 2017 Mar; 18(3):166-176. PubMed ID: 28368741
[TBL] [Abstract][Full Text] [Related]
27. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2.
Molhoek KR; Griesemann H; Shu J; Gershenwald JE; Brautigan DL; Slingluff CL
Cancer Res; 2008 Jun; 68(11):4392-7. PubMed ID: 18519701
[TBL] [Abstract][Full Text] [Related]
28. A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.
Kurenova E; Ucar D; Liao J; Yemma M; Gogate P; Bshara W; Sunar U; Seshadri M; Hochwald SN; Cance WG
Cell Cycle; 2014; 13(16):2542-53. PubMed ID: 25486195
[TBL] [Abstract][Full Text] [Related]
29. PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity.
Incio J; Tam J; Rahbari NN; Suboj P; McManus DT; Chin SM; Vardam TD; Batista A; Babykutty S; Jung K; Khachatryan A; Hato T; Ligibel JA; Krop IE; Puchner SB; Schlett CL; Hoffmman U; Ancukiewicz M; Shibuya M; Carmeliet P; Soares R; Duda DG; Jain RK; Fukumura D
Clin Cancer Res; 2016 Jun; 22(12):2993-3004. PubMed ID: 26861455
[TBL] [Abstract][Full Text] [Related]
30. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma.
Wu Y; Hooper AT; Zhong Z; Witte L; Bohlen P; Rafii S; Hicklin DJ
Int J Cancer; 2006 Oct; 119(7):1519-29. PubMed ID: 16671089
[TBL] [Abstract][Full Text] [Related]
31. Structural determinants of growth factor binding and specificity by VEGF receptor 2.
Leppänen VM; Prota AE; Jeltsch M; Anisimov A; Kalkkinen N; Strandin T; Lankinen H; Goldman A; Ballmer-Hofer K; Alitalo K
Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2425-30. PubMed ID: 20145116
[TBL] [Abstract][Full Text] [Related]
32. Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role.
Wang X; Bove AM; Simone G; Ma B
Front Cell Dev Biol; 2020; 8():599281. PubMed ID: 33304904
[TBL] [Abstract][Full Text] [Related]
33. The Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) D16F7 Monoclonal Antibody Inhibits Melanoma Adhesion to Soluble VEGFR-1 and Tissue Invasion in Response to Placenta Growth Factor.
Atzori MG; Ceci C; Ruffini F; Scimeca M; Cicconi R; Mattei M; Lacal PM; Graziani G
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428669
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
Takahashi S
Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
[TBL] [Abstract][Full Text] [Related]
35. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2.
Zhang Z; Neiva KG; Lingen MW; Ellis LM; Nör JE
Cell Death Differ; 2010 Mar; 17(3):499-512. PubMed ID: 19834490
[TBL] [Abstract][Full Text] [Related]
36. Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice.
Malik AK; Baldwin ME; Peale F; Fuh G; Liang WC; Lowman H; Meng G; Ferrara N; Gerber HP
Blood; 2006 Jan; 107(2):550-7. PubMed ID: 16189273
[TBL] [Abstract][Full Text] [Related]
37. Heparanase and vascular endothelial growth factor expression in the progression of oral mucosal melanoma.
Rivera RS; Nagatsuka H; Siar CH; Gunduz M; Tsujigiwa H; Han PP; Katase N; Tamamura R; Ng KH; Naomoto Y; Nakajima M; Nagai N
Oncol Rep; 2008 Mar; 19(3):657-61. PubMed ID: 18288398
[TBL] [Abstract][Full Text] [Related]
38. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis.
Shirakami Y; Shimizu M; Adachi S; Sakai H; Nakagawa T; Yasuda Y; Tsurumi H; Hara Y; Moriwaki H
Cancer Sci; 2009 Oct; 100(10):1957-62. PubMed ID: 19558547
[TBL] [Abstract][Full Text] [Related]
39. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
[TBL] [Abstract][Full Text] [Related]
40. VEGF-A promotes the motility of human melanoma cells through the VEGFR1-PI3K/Akt signaling pathway.
Koizumi K; Shintani T; Hayashido Y; Hamada A; Higaki M; Yoshioka Y; Sakamoto A; Yanamoto S; Okamoto T
In Vitro Cell Dev Biol Anim; 2022 Sep; 58(8):758-770. PubMed ID: 35997849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
